Clear cell sarcoma of soft tissue (malignant melanoma of soft parts) is a soft tissue sarcoma with melanocytic differentiation that typically occurs in the tendons and aponeuroses of young adults. As demonstrated by cytogenetics and reverse-transcriptase polymerase chain reaction, between 70% and over 90% of clear cell sarcomas have a t(12;22) translocation, fusing the EWS and ATF1 genes on chromosomes 22q12 and 12q13, respectively. Identification of this translocation distinguishes clear cell sarcoma from histologic mimics, most importantly conventional malignant melanoma. We report our experience with a commercially available, dualcolor, break-apart fluorescence in situ hybridization (FISH) probe, which allows detection of EWS (22q12) gene rearrangement in formalin-fixed, paraffin-embedded tissues. Histologically and immunophenotypically wellcharacterized cases of clear cell sarcoma (n ¼ 10) and malignant melanoma (n ¼ 32) were evaluated with a 22q12 dual-color, break-apart probe (Vysis, Downer's Grove, IL, USA), which spans the known common breakpoints in the EWS gene on chromosome 22 (introns 7-10). Signals from tumor cell nuclei were counted under a fluorescence microscope and the presence of red-green break-apart signals was recorded. Of the clear cell sarcoma cases, seven of 10 showed evidence of an EWS gene rearrangement with a mean of 81.6% positive cells per sample (range: 60-95%). All cases of malignant melanoma (n ¼ 32) showed virtually absent break-apart signals in the EWS gene (less than 4% cells per case). FISH detects EWS gene rearrangement in a substantial proportion of clear cell sarcomas, with excellent specificity. Importantly, EWS FISH is negative in malignant melanoma, a clinically dissimilar tumor, which may closely mimic clear cell sarcoma histologically and immunohistochemically. As the studied probe can be utilized in routinely processed tissue, FISH provides an excellent alternative to reverse-transcriptase polymerase chain reaction in cases where fresh tissue is unavailable. Modern Pathology ( Clear cell sarcoma of soft tissue (malignant melanoma of soft parts) is a rare soft tissue sarcoma with melanocytic differentiation first described by Enzinger 1 in 1965. The tumor originates predominantly in the tendons, aponeuroses, and fascial structures of the extremities of young adults. [1] [2] [3] [4] [5] Clear cell sarcoma shares morphologic, immunohistochemical, ultrastructural, and molecular features with malignant melanoma. 2, [6] [7] [8] [9] [10] In contrast to malignant melanoma, a unique and recurrent t(12;22)(q13;q12) involving the EWS gene has been identified in 70% to over 90% of clear cell sarcomas by cytogenetics, reverse-transcriptase polymerase chain reaction (RT-PCR) looking for the resultant EWS-ATF1 fusion protein, and by fluorescence in situ hybridization (FISH).
Clear cell sarcoma of soft tissue (malignant melanoma of soft parts) is a rare soft tissue sarcoma with melanocytic differentiation first described by Enzinger 1 in 1965. The tumor originates predominantly in the tendons, aponeuroses, and fascial structures of the extremities of young adults. [1] [2] [3] [4] [5] Clear cell sarcoma shares morphologic, immunohistochemical, ultrastructural, and molecular features with malignant melanoma. 2, [6] [7] [8] [9] [10] In contrast to malignant melanoma, a unique and recurrent t(12;22)(q13;q12) involving the EWS gene has been identified in 70% to over 90% of clear cell sarcomas by cytogenetics, reverse-transcriptase polymerase chain reaction (RT-PCR) looking for the resultant EWS-ATF1 fusion protein, and by fluorescence in situ hybridization (FISH). [11] [12] [13] [14] [15] [16] [17] [18] [19] Clear cell sarcoma is rare and the true incidence of this neoplasm is not well established; however, the increased utilization of molecular studies for the identification of the characteristic translocation may help to better define its incidence in the future. Although clear cell sarcoma is rare relative to malignant melanoma, it should be a diagnostic consideration in patients who present with a tumor with the requisite histologic features and no history of a primary cutaneous or mucosal melanoma. The significance of distinguishing between these two entities is of great consequence in light of the fact that metastatic melanoma (AJCC stage IV melanoma) has a median survival rate of 7.5 months and an estimated 5-year survival rate of 6%, 20 a prognosis much different from clear cell sarcoma, which in the few studies with long-term follow-up and large cohorts, has 5, 10, and 20 year survival rates of 67%, 33%, and 10%, respectively.
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A dual-color, break-apart FISH probe, which allows detection of EWS (22q12) gene rearrangement in formalin-fixed, paraffin-embedded tissues, has recently become commercially available and could potentially serve as an alternative ancillary diagnostic tool in situations where fresh tissue is not available for classical cytogenetics and/or RT-PCR. Herein we report our experience utilizing this probe for distinguishing clear cell sarcoma from its most important histological mimic, malignant melanoma.
Materials and methods
The study was performed on histologically and immunophenotypically well-characterized cases of clear cell sarcoma (n ¼ 10) and malignant melanoma (n ¼ 32), using both conventional whole-tissue sections and a tissue microarray. After Institutional Review Board approval, tissues were obtained from resection specimens or excisional biopsies from the Department of Anatomic Pathology at the Cleveland Clinic Foundation and the soft tissue consultation service of the Department of Pathology at Emory University. All cases were reviewed by three experienced soft tissue pathologists (SWW, JRG, and ALF) and an experienced dermatopathologist (RJT).
All tissue was neutral buffered formalin-fixed and paraffin-embedded. Whole-tissue sections stained with hematoxylin and eosin were evaluated for tumor and appropriate areas were scored for tissue microarray construction. Cases were arrayed in duplicate 1.5-mm cores. After array construction, 4-mm sections were placed on electrostatically charged slides (Superfrost; Fisher; Hampton, NH, USA), with the last section stained with hematoxylin and eosin to confirm the presence of tumor. The clear cell sarcoma whole-tissue sections and the tissue microarray were then subjected to direct FISH using the EWS (22q12) dual-color, break-apart probe (Vysis, Downer's Grove, IL, USA), which spans the known common breakpoints in the EWS gene on chromosome 22 (introns 7-10). The 1100 kb probe specific for the 3 0 (telomeric) side of EWS was labeled in Spectrum Green and the 500 kb probe specific for the 5 0 (centromeric) side of EWS was labeled in Spectrum Orange. FISH was performed according to the manufacturer's instructions and established laboratory protocol. The tissue microarray was then scored by evaluating 100 tumor cell nuclei per case with fluorescence microscopy. Cells that have the chromosomal rearrangement will have a discreet red signal distanced from a discreet green signal, indicating a translocation involving one EWS allele, while the second allele will be intact with a red and a green signal which are opposed (less commonly, both chromosomes in the same cell may show this rearrangement and occasionally, more than two copies of chromosome 22 may be seen with a variable number of rearranged chromosomes present). The interpretation of intact and split signals was based on generally accepted guidelines recommended by Vysis and used for all other commercially available break-apart FISH assays in clinical laboratories performing testing using this method. This approach requires the space between two signals to be greater than one signal width in order to be considered a split signal. Cells without the rearrangement will have two sets of red and green opposed signals, indicating two intact EWS alleles. In keeping with other FISH assays validated for paraffin-embedded tissue in our laboratory, a positive result was reported when greater than 10% of the tumor nuclei had evidence of an EWS rearrangement. To avoid false-positives resulting from nuclear truncation occurring in a subset of cells in paraffin-embedded samples, only tumor nuclei with all four signals present were evaluated, and overlapping cells indistinguishable as separate nuclei were excluded from the analysis.
Results
Our laboratory has validated the EWS (22q12) probe from Vysis, Inc. in formalin-fixed and paraffinembedded tissues. Testing for the presence of an EWS-FLI1 fusion transcript by RT-PCR was undertaken in fresh-frozen tissues from cases indexed as Ewing's sarcoma (n ¼ 8), alveolar rhabdomyosarcoma (n ¼ 2), lymphoblastic lymphoma (n ¼ 1), and small cell carcinoma (n ¼ 1). The EWS-FLI1 fusion transcript was found to be present in 8/8 (100%) of the Ewing's sarcoma cases, while the fusion transcript was not identified in the other neoplasms studied. FISH using the EWS (22q12, Vysis, Inc.) break-apart probe was then performed in the corresponding formalin-fixed, paraffin-embedded tissues from these cases. A total of 100 tumor nuclei per case were evaluated, blinded to the RT-PCR results. All eight cases of Ewing's sarcoma had evidence of a rearrangement involving EWS, with a mean of 70% positive nuclei per 100 tumor nuclei (range: 62-85% positive nuclei per 100 tumor nuclei, mean: 70.25, s.d.: 8.76). The remaining neoplasms were essentially devoid of any rearrangement involving the EWS gene (range: 1-4% positive nuclei per 100 tumor nuclei, mean: 1.8, s.d.: 1.48). This distribution establishes a probe-specific normal range of less than or equal to 4% (4.76 respectively, if two standard deviations from the mean are used for calculation of this cutoff), and establishes that the EWS (22q12) probe shows excellent sensitivity and specificity for identifying the common breakpoints at 22q12. (Figures 2 and 3) . Although the morphology varied, malignant melanoma cases were characterized by an epidermal junctional component and immunoreactivity for S-100 and at least one melanocyte-specific marker.
Of the clear cell sarcomas, 7/10 cases showed evidence of an EWS gene rearrangement with a mean of 81.6% positive cells per sample (range: 60-95%) (Figure 4 ). RT-PCR correlation was available for two of the clear cell sarcomas (performed as a send-out test at the time of diagnosis to Dr Frederick Barr's Molecular Pathology Laboratory at the University of Pennsylvania, Philadelphia, PA, USA). The clear cell sarcoma FISH and RT-PCR results were correlative, with one EWS FISH-positive case having the EWS-ATF1 fusion transcript, and one EWS FISH-negative case not having the EWS-ATF1 fusion transcript identified. All 32 cases of malignant melanoma showed virtually absent break-apart signals in the EWS gene region (fewer than 4% cells per case) ( Table 1) .
Two of the clear cell sarcoma cases that were represented on the tissue microarray were negative for the EWS gene rearrangement by FISH. To ensure that sampling was not a cause for this result, whole tissue sections from these cases were reassessed with the EWS FISH probe and the results remained the same. 
Discussion
Clear cell sarcoma of soft tissue and malignant melanoma share morphological, immunohistochemical, ultrastructural, and molecular features. Both can demonstrate melanin synthesis and are immunoreactive for S-100 protein, and melanocyte-specific markers HMB-45 and MITF, among others. 6, 9, 19, 24 Shared ultrastructural features of melanocytic differentiation include cytoplasmic melanosomes and the presence of an external lamina. 6 At the molecular level, alterations of the p16INK4a/ p14ARF pathway are present in both clear cell sarcoma and malignant melanoma. 25 Although originally reported to be genetically distinct from malignant melanoma, 16 recent genomic profiling data suggest that clear cell sarcoma is a subtype of melanoma. 26 However, in contradistinction to malignant melanoma, clear cell sarcoma harbors EWS gene rearrangements in up to 90% of cases. [11] [12] [13] [14] [15] [16] [17] [18] [19] 27 Thus, translocations involving EWS are diagnostically useful for distinguishing clear cell sarcoma from its most important mimic malignant melanoma. 19 Although not a hypothesis tested in this study, clear cell sarcoma could conceivably be distinguished from benign melanocytic proliferations that mimic malignant melanoma, such as cellular blue nevi, deep penetrating nevi, and proliferative nodules arising within congenital nevi, as these lesions have not been reported to contain EWS gene rearrangements. 28, 29 The t(12;22) translocation fuses the EWS gene on chromosome 22 with the ATF gene on chromosome 12. 30 This translocation was first demonstrated by Bridge and co-workers 11, 31 by classical cytogenetics, and subsequently confirmed by others [12] [13] [14] in shortterm and continuous cell culture lines. 32, 33 To date, four separate fusion transcripts have been described in the literature. 17, 18 The most common fusion transcript, found in approximately 87% of trans location-positive cases with fusion structure data, 17 consists of an EWS exon 8 fusion to ATF1 codon 65, as described by Zucman et al. 34 The other three EWS-ATF1 variant transcripts are rare, accounting for approximately 10% of cases. 35 The EWS-ATF-1 36 whose mechanism of action appears to be targeted repression of the CBP/p300 transcriptional coactivator, resulting in loss of function of p53. 37 Although not diagnostically helpful, polysomy of chromosome 8 is another common cytogenetic abnormality in clear cell sarcoma. 11, 31 Other molecular characteristics which may have diagnostic utility in the future include activating mutations in the BRAF gene, which have been demonstrated in a significant percentage of malignant melanoma, but not clear cell sarcoma, 38 and the protein product of the epidermal growth factor receptor ERBB3 gene, which has been reported to be a marker of clear cell sarcoma. 39 A diagnostic dilemma arises when the pathologist is confronted with a malignant melanoma of unknown primary, where histologic, immunophenotypic, and clinical features resemble clear cell sarcoma. In this circumstance, cytogenetic examination of fresh tissue remains the gold standard, as it may reveal prognostically relevant karyotpic changes in addition to the t(12;22)(q13;q12). 27 When fresh tissue is unavailable, FISH and/or RT-PCR are methods applicable to formalin-fixed, paraffinembedded tissues. Unfortunately, specific problems arise from RT-PCR of archival tissue due to degradation of RNA and insufficient extraction efficiency. 40 For this reason, RT-PCR utilizing fresh-frozen tissue has a 10-to 50-fold greater sensitivity for detection of chimeric gene fusions in soft tissue sarcomas than RT-PCR using paraffin-embedded tissue. 41 Similar results to those achieved in frozen tissues can be attained from archival material by the addition of a nested RT-PCR step, 17 but this is time consuming and labor intensive. In addition, the high sensitivity of this method may increase false-positive results. In contrast to cytogenetics and RT-PCR, FISH represents a cost-and time-efficient method, which can be undertaken utilizing paraffin-embedded, formalin-fixed tissue. Our laboratory has found that tissue microarrays assembled from formalin-fixed tissue are a useful tool for evaluating immunohistochemical stains and for performing FISH. Tissue microarrays allow for evaluation of large numbers of cases, are cost-effective in that they require less probe and reagents, are less time consuming for the technologist, conserve tissue, and yield reproducible results. 42 Our study demonstrates that dual-color, breakapart, interphase FISH detects EWS gene rearrangement in a substantial proportion of clear cell sarcomas, with excellent specificity, a finding consistent with previous studies. 30, 34 The relative lack of sensitivity of this probe may be explained by variant translocations, or an alternative molecular pathogenesis in the FISH-negative tumors; further studies of these cases utilizing alternative methods are indicated. In this series, three clear cell sarcomas were found to be negative for the EWS rearrangement by FISH. As two of these cases were scored from the tissue microarray, conventional whole histologic sections from these cases were subjected to repeat analysis by FISH and were negative for EWS rearrangement with repeat testing. The third FISH-negative case had correlative negative RT-PCR for the EWS-ATF1 fusion transcript. Given the sensitivity and specificity of the probe in this series, we believe that these are true fusion-negative cases.
The most important finding in this study is that EWS FISH is negative in malignant melanoma and therefore highly specific for clear cell sarcoma in this differential diagnosis. FISH can be performed on uncultured cells, including those from frozen tissue. However, in cases where fresh tissue is unavailable, FISH evaluation of formalin-fixed, paraffin-embedded tissue appears to be an important ancillary diagnostic test, in that it represents an alternative to RT-PCR for making the distinction between clear cell sarcoma and its most important mimic, malignant melanoma.
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